STXS

Stereotaxis, Inc. 10-Q Summary: Quarter Ended March 31, 2005

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2005. Stereotaxis, Inc. designs, manufactures, and markets the NIOBE cardiology magnet system, an advanced instrument control system used in interventional surgical suites to guide catheters and guidewires via magnetic fields. The company is in the early stages of commercialization, relying on collaborations with major medical device firms (Siemens, Philips, J&J) for system integration and distribution.

Key Financial Metrics

Liquidity: As of March 31, 2005, the company held approximately $38.3 million in liquid assets (cash, cash equivalents, and short-term investments). The company maintains an $8.0 million revolving line of credit with no outstanding borrowings.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 65% year-over-year, driven primarily by a 73% increase in systems revenue ($4.63 million vs. $2.67 million). This was attributed to a higher average selling price and a shift in product mix toward the advanced NIOBE II system (80% of recognized systems in Q1 2005 vs. 80% NIOBE I in Q1 2004).
• Margin Expansion: Gross margin improved significantly to 52.1% from 19.2% in the prior year, despite cost of revenue remaining relatively flat ($2.44 million vs. $2.48 million).
• Expense Increases: Operating expenses rose to $10.13 million from $8.46 million. General and Administrative expenses increased 70% due to public company compliance costs and commercialization activities. Sales and Marketing expenses increased 41% due to hiring and expanded programs. Research and Development expenses decreased 12% due to timing of project expenditures.
• Cash Flow: Net cash used in operating activities decreased to $7.32 million from $8.99 million. Investing activities provided $16.2 million, primarily from the sale of available-for-sale investments.

Guidance, Outlook, and Risks

Outlook: Management expects negative cash flow from operations to continue through at least the first half of 2006. The company anticipates that existing cash and investment resources will be sufficient to fund operations for at least the next 12 months, though additional financing may be required.

Accounting Changes: The company must adopt SFAS No. 123(R) effective January 1, 2006, which will require fair value recognition of stock-based compensation, expected to decrease reported earnings.

Key Risks:

• Commercialization: Success depends on hospital adoption of expensive capital equipment and physician training. Sales cycles are long (6-8 months) and subject to construction delays.
• Collaborations: Revenue relies heavily on partnerships with Siemens, Philips, and J&J. Failure of these partners to integrate technology or co-market products could materially harm the business.
• Regulatory: Future growth depends on FDA clearances for new disposable devices. Delays or denials would limit market expansion.
• Competition: The company faces competition from established manual interventional methods and emerging non-magnetic navigation devices.

Investor Verification Checklist

• Revenue Recognition Timing: Verify the status of outstanding purchase orders and installation schedules, as revenue is recognized upon installation for end-users, creating potential volatility.
• Collaboration Performance: Monitor the progress of technology integration and co-marketing efforts with Siemens, Philips, and J&J.
• Regulatory Pipeline: Track the status of FDA 510(k) clearances for new disposable interventional devices, which are critical for recurring revenue.
• Cash Burn Rate: Assess the runway of current liquid assets ($38.3 million) against the projected negative operating cash flow through 2006.
• Stock-Based Compensation Impact: Review the pro-forma impact of the upcoming SFAS 123(R) adoption on future net loss figures.